Breathe Well Live Well
|
Glaxo Settlement Pull Back Curtain On Drug Marketing
NPR (blog) The government alleged that Glaxo promoted Advair, an asthma remedy combining two drugs, for use as a first-choice treatment for just about anybody with asthma. The Food and Drug Administration, concerned about risks, took a much narrower view and … |
View full post on asthma – Google News
|
SkyePharma's asthma drug gets European marketing nod
Reuters Company sees launching drug across Europe in H2* Stock up 28 pct, top percentage gainer on LSEJuly 3 (Reuters) – Britain's SkyePharma Plc said itsasthma therapy Flutiform got marketing approval from. |
View full post on asthma – Google News
|
AstraZeneca Set To Gain From New Asthma Drug
Seeking Alpha AstraZeneca and Rigel Pharmaceuticals (RIGL) have agreed to work together on a chronic asthma drug. The drug in question is R256, which is Rigel's "inhaled … |
View full post on asthma – Google News
|
Astellas gets expanded approval for Symbicort asthma drug in Japan
Reuters TOKYO, June 22 (Reuters) – Astellas Pharma Inc saidon Friday it has received approval for additional use of itsSymbicort Turbuhaler drug treatment for adult … |
View full post on asthma – Google News
|
AstraZeneca, Rigel Sign Potentially $100M Asthma Drug Deal
Genetic Engineering News Drug firm will start first-in-man studies and carry out clinical development program for R256. |
View full post on asthma – Google News
|
Global asthma and COPD drug market to reach nearly $27 billion in …
The Pharma Letter The global asthma and chronic obstructive pulmonary disease (COPD) market was worth $25.102 billion in 2010, and is expected to reach $26.965 billion in … |
View full post on asthma – Google News
|
Rigel, AstraZeneca strike potential $100M asthma drug deal
Bizjournals.com (blog) AstraZeneca will license an experimental asthma treatment from South San Francisco's… |
View full post on asthma – Google News
 Proactive Investors USA & Canada |
AstraZeneca to join Rigel in asthma drug venture
The News Journal AstraZeneca will join with Rigel Pharmaceutical Inc. to develop a treatment for chronic asthma that could be worth $100 million, if the drug can manage the … AstraZeneca partners with Rigel on asthma drug AstraZeneca and Rigel strike asthma deal worth up to $100M AstraZeneca And Rigel Sign Worldwide License Agreement For A … |
View full post on asthma – Google News
|
AstraZeneca partners with Rigel on asthma drug
CBS News NEW YORK — Rigel Pharmaceuticals Inc. plans to work with AstraZeneca PLC to develop an experimental asthma drug as part of a deal that could be worth … AstraZeneca and Rigel strike asthma deal worth up to $100M AstraZeneca And Rigel Sign Worldwide License Agreement For A … AstraZeneca, Rigel to Develop Asthma Treatment |
View full post on asthma – Google News
|
Asthma and COPD Drug Market Expected to Reach USD 26965.5 …
MarketWatch (press release) The asthma market is witnessing intense competition due to the increased entry of inhaled corticosteroids, combinational therapies, and beta-agonists. |
View full post on asthma – Google News